Amylyx Pharmaceuticals, Inc. (AMLX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Product revenue, net | - | - | - | |
| Acquired in-process research and development | - | - | 36,203 | |
| Selling, general and administrative | 15,640 | 15,684 | 17,828 | |
| Restructuring expenses | - | - | - | |
| Research and development | 27,217 | 22,119 | 21,237 | |
| Cost of sales | - | - | - | |
| Cost of sales - inventory impairment and loss on firm purchase commitments | - | - | 809 | |
| Total operating expenses | 42,857 | 37,803 | 76,077 | |
| Product revenue, net | - | - | 416 | |
| Loss from operations | -42,857 | -37,803 | -75,661 | |
| Other expense, net | -546 | -335 | -141 | |
| Interest income | 1,960 | 2,231 | 3,098 | |
| Total other income, net | 1,414 | 1,896 | 2,957 | |
| Loss before income taxes | -41,443 | -35,907 | -72,704 | |
| Provision for income taxes | - | - | - | |
| Net loss | -41,443 | -35,907 | -72,704 | |
| Earnings per share, basic, total | -0.46 | -0.42 | -1.07 | |
| Earnings per share, diluted, total | -0.46 | -0.42 | -1.07 | |
| Weighted average number of shares outstanding, basic, total | 89,138,568 | 85,697,108 | 68,091,446 | |
| Weighted average number of shares outstanding, diluted | 89,138,568 | 85,697,108 | 68,091,446 | |